Contact Us
Search website   
 PUBLICATIONS

» Back to All Publication Categories
1-20 | 21-26

Drug-Drug Interactions (DDI)

Ascendingitem name
Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P and Parkinson A
(2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J and Wrighton SA
(2003) The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective.  J Clin Pharmacol  43:443-469.
Madan A, Usuki E, Burton LA, Ogilvie BW and Parkinson A
(2002) In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs, in: Drug-Drug Interactions (Rodrigues AD ed), pp 217-294, Marcel Dekker, Inc., New York, NY. 
Dresser GK, Spence JD and Baily DG
(2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57.
Thompson T
A strategy for use of in vitro metabolism studies to evaluate potential drug-drug interactions: M100907 as a case study in “Predicting Drug Metabolism”. AdvanceTech Monitor, Woburn MA, 96-106, 2000.
Venkatakrishnan K, von Moltke LL and Greenblatt DJ
(2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111-180.
Barry M, Mulcahy F, Merry C, Gibbons S and Back D
(1999) Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 36:289-304.
Crespi CL and Miller VP
(1999) The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol Ther 84:121-131.
Fang J and Gorrod JW
(1999) Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol 19:491-510.
Rodrigues AD
(1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
Tseng AL and Foisy MM
(1999) Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother 33:461-473.
Clarke SE
(1998) In vitro assessment of human cytochrome P450. Xenobiotica 28:1167-1202.
Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y and Sugiyama Y
(1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499.
Lin JH and Lu AY
(1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
Loiseau P
(1998) Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance. Drug Safety 19:495-510.
Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A and Raunio H
(1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203-1253.
Power BM, Forbes AM, van Heerden PV and Ilett KF
(1998) Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 34:25-26.
Szklarz G and Halpert J
(1998) Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab Dispos 26:1179-1184.
Tanaka E
(1998) Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 23:403-416.
Thummel KE and Wilkinson GR
(1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
1-20 | 21-26
» Back to All Publication Categories
Home | Products | Contract Services | Resource Library | Calendar Of Events | About XenoTech | contact us